Chest
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: QVA149 is a once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist (indacaterol) and long-acting muscarinic antagonist glycopyrronium, for the treatment of COPD. We evaluated the overall rate of exacerbations and the health status with QVA149 in comparison with glycopyrronium and tiotropium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Peter D'Andrea: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Christie Arrasate: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Hungta Chen: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals CorporationClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Indacaterol is an ultra-long-acting beta-adrenoceptor agonist which needs to be taken once a day, licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler. A year-long, placebo-controlled trial published in July 2010 suggests indacaterol may be significantly more effective than twice-daily formoterol in improving FEV1. There were some reductions in the need for rescue medication, but these were not significantly different; nor was there any difference in the rate of exacerbation between the 2 active treatments. We looked at our data regarding the use of Indacaterol in a tertiary care set up. This is a real life experience looking at how Indacaterol influences clinical (MRC dyspnoea scale) and physiological (Spirometry) parameters and exacerbation episodes. ⋯ The following authors have nothing to disclose: Raja Dhar, Sanjit Ray ChaudhuriNo Product/Research Disclosure Information.
-
Surgery Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Bronchogenic cysts are developmental anomalies of the ventral foregut arising from abnormal budding of the primitive tracheobronchial tree. Usually they acquire an intra-thoracic location primarily mediastinal or intraparenchymal, though atypical locations including cervical, intradiaphragmatic, interatrial septum and retroperitoneal have been reported. We present an extremely rare, aberrant location of a bronchogenic cyst within the thymic tissue that was minimally resected with robotic assistance. ⋯ The following authors have nothing to disclose: Maria Siddiqui, Adnan Al-Ayoubi, Sadiq Rehmani, Faiz BhoraNo Product/Research Disclosure Information.
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Non-cystic fibrosis bronchiectasis is a multicomponent disease associated with increased morbidity and mortality. Using data from 608 patients attending a specialist bronchiectasis clinic in Edinburgh, UK, the Bronchiectasis Severity Index (BSI) has recently been developed as a composite clinical prediction tool in bronchiectasis. The score consists of 8 commonly measured clinical parameters reflecting age, BMI, MRC dyspnoea score, FEV1%, bacterial colonisation, radiological extent, exacerbation frequency and prior hospitalization with subsequent classification into low, intermediate and high risk groups. ⋯ The following authors have nothing to disclose: Melissa McDonnell, James Chalmers, Pieter Goemmine, Stefano Aliberti, Sara Lonni, John Davison, Lucy Poppelwell, Walid Salih, Alberto Pesci, Lieven Dupont, Thomas Fardon, Adam Hill, Anthony De SoyzaNo Product/Research Disclosure Information.
-
DVT/PE PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chest computed tomography (CT) has replaced angiography and ventilation/perfusion scanning as the diagnostic method of choice for pulmonary embolism. This study reviews the indications and outcomes of chest CT scanning in the setting of a non-trauma based community hospital Emergency Department (ED) in an effort to develop a "best practice" guideline that optimizes patient care while minimizing radiation exposure and cost. ⋯ The following authors have nothing to disclose: Thomas Willson, Benjamin Larsen, Matthew Blecha, Mark Connolly, Francis PodbielskiNo Product/Research Disclosure Information.